Garg Scot, Serruys Patrick
Department of Interventional Cardiology, Thoraxcentre, Erasmus Medical Center, Gravendijkwal 230, Rotterdam, The Netherlands.
Expert Rev Cardiovasc Ther. 2010 Mar;8(3):449-70. doi: 10.1586/erc.09.138.
Drug-eluting coronary stents are being used with increasing frequency in patients undergoing percutaneous coronary intervention. Although these stents have shown remarkably low rates of restenosis compared with their predecessors, there have been increasing concerns lately regarding their safety. Extensive data have been published that demonstrate a higher risk of very late stent thrombosis with drug-eluting stents; however, this has not had any impact on long-term mortality or the risk of myocardial infarction when compared with bare-metal stents. Their overall net clinical benefit therefore still favors their use. Recent research has led to a greater understanding of the multifactorial cause of stent thrombosis, which has enabled measures to be taken to reduce an individual patient's risk. In the future, new stent designs and new antiplatelet agents may help to reduce this risk further.
药物洗脱冠状动脉支架在接受经皮冠状动脉介入治疗的患者中使用频率越来越高。尽管与前代产品相比,这些支架的再狭窄率显著降低,但最近人们对其安全性的担忧日益增加。已发表的大量数据表明,药物洗脱支架发生极晚期支架血栓形成的风险更高;然而,与裸金属支架相比,这对长期死亡率或心肌梗死风险没有任何影响。因此,它们的总体净临床获益仍然支持其使用。最近的研究使人们对支架血栓形成的多因素病因有了更深入的了解,这使得能够采取措施降低个体患者的风险。未来,新的支架设计和新的抗血小板药物可能有助于进一步降低这种风险。